Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 5, September-October, p. 881–887

Publication type: review article

Language: Polish

WT1 – nowy marker komórek białaczkowych

WT1 – a New Marker of Leukaemic Cells

Beata Piątkowska−Jakubas1,, Alicja Nowakowska−Kopera1,, Aleksander B. Skotnicki1,

1 Katedra i Klinika Hematologii CM UJ w Krakowie

Streszczenie

Gen WT1 znajduje się na chromosomie 11p13 i koduje czynnik transkrypcyjny o budowie palca cynkowego dla białek odpowiedzialnych za regulację wzrostu i różnicowania komórkowego. Jego ekspresję wykazano podczas rozwoju embrionalnego różnych tkanek zwierzęcych, a także w tkankach nowotworowych u ludzi oraz w ostrych białaczkach. Ekspresja WT1 na komórkach blastycznych większości ostrych białaczek i jej brak na prawidłowych komórkach hemopoetycznych, w tym komórkach progenitorowych CD34+ pozwala na użycie go jako nowego markera służącego do oceny minimalnej choroby resztkowej u chorych na ostre białaczki. Nadekspresję genu WT1 wykazano w przewlekłej białaczce szpikowej oraz guzach litych. Białko WT1 indukuje wytwarzanie swoistych cytotoksycznych limfocytów T i może być antygenem docelowym w celowanej immunoterapii chorób nowotworowych.

Abstract

The WT1 gene is located on chromosome 11p13 and encodes a zinc finger motif−containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues in animal models as well as in a few human malignancies including acute leukemias. Its expression in the majority of human acute leukemias but not in normal mononuclear blood cells and normal CD34+ hematopoietic progenitors qualifies the WT1 gene transcript as a ‘pan−acute leukemic’ marker probably useful in monitoring minimal residual disease after chemotherapy. WT1 is overexpressed in chronic myeloid leukemia and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies induceing WT1−specific cytotoxic T lymphocytes.

Słowa kluczowe

embriogeneza, leukemogeneza, ostre białaczki, MDS, PBS, minimalna choroba resztkowa, immunoterapia

Key words

embryogenesis, leukaemogenesis, acute leukaemias, MDS, CML, minimal residual disease, immunotherapy

References (68)

  1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier I, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990, 60, 509–520.
  2. Rose EA, Glaser T, Jones C, Smith CL, Lewis WH, Call KM, Minden M, Champagne E, Bonetta L, Yeger H, Housman DE: Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms’ tumor gene. Cell 1990, 60, 405–508.
  3. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci 1991, 88, 9618–9622.
  4. Laity JH, Dyson HJ, Wright PE: Molecular basis for modulation of biological function by alternate splicing of the Wilms’ tumor suppressor protein. Proc Nat Acad Sci 2000, 97, 11932–11935.
  5. Pritchard−Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D: The candidate Wilms’ tumour gene is involved in genitourinary development. Nature 1990, 346,194–197.
  6. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B: Nuclear localization of the protein encoded by the Wilms’ tumor gene WT1 in embryonic and adult tissues. Development 1993, 119, 1329–1341.
  7. Miwa H, Beran M, Saunders GF: Expression of the Wilms’ tumor gene (Wt1) in human leukemias. Leukemia 1992, 6, 405–409.
  8. Bruening W, Gros P, Sato T, Housman D, Pelletier J: Analysis of the 11p13 Wilms’ tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993, 11, 393–399.
  9. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfi T, Maurer J, Thiel E, Menssen HD: Expression of the Wt1 Wilms’ tumor gene by normal and malignant human melanocytes. Int J Cancer 1994, 59, 78–82.
  10. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW: Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci 1997, 94, 8132–8137.
  11. Tisljar K, Linnerth B, Priglinger S: Detection of WT1 gene expression in patients with solid tumors. Br J Haematol 1996, 93, 201.
  12. Hossain A, Saunders GF: The human sex−determining gene SRY is a direct target of WT1. J Biol Chem 2001, 276, 16817–16823.
  13. Wagner K D, Wagner N, Vidal VPI, Schley G, Wilhelm D, Schedl A Englert C, Scholz H: The Wilms’ tumor gene Wt1 is required for normal development of the retina. EMBO J 2002, 21, 1398–1405.
  14. Miyagawa K, Kent J, Moore A, Charlieu J−P, Little MH, Williamson KA, Kelsey A, Brown KW, Hassam S, Briner J, Hayashi Y, Hirai H, Yazaki Y, van Heyningen V, Hastie ND: Loss of WT1 function leads to ectopic myogenesis in Wilms’ tumour. (Letter) Nature Genet 1998, 18, 15–17.
  15. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT−1 is required for early kidney development. Cell 1993, 74, 679–691.
  16. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA: The Wilms tumor suppressor WT1 directs stagespecific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001, 20, 1897–1909.
  17. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996, 12, 1005–1014.
  18. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996, 87, 2878–2884.
  19. Hosoya N, Miyagawa K, Mitani K, Yazaki Y, Hirai H: Mutation analysis of the WT1 gene in myelodysplastic syndromes. Jpn J Cancer Res 1998, 89, 821–824.
  20. King−Underwood L, Pritchard−Jones K: Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998, 91, 2961–2968.
  21. Fukahori S: Quantification of WT1 mRNA by competitive NASBA in AML patients. Kurume Med J 2001, 48, 129–134.
  22. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P, Schmidt CA: Fluorescent 5’−exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001, 114, 313–318.
  23. Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E: Expression of Wilms’ tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004, 83, 745–750.
  24. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N, Ikegame K, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Osumi K, Soma T, Oji Y, Oka Y, Kawase I, Sugiyama H, Ogawa H: Monitoring minimal residual disease in leukemia using real−time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003, 78, 349–356.
  25. Yanada M, Terakura S, Yokozawa T, Yamamoto K, Kiyoi H, Emi N, Kitamura K, Kohno A, Tanaka M, Tobita T, Takeo T, Sao H, Kataoka T, Kobayashi M, Takeshita A, Morishita Y, Naoe T, Sugiura I: Multiplex real−time RT−PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004, 45, 1803–1808.
  26. Patmasiriwat P, Fraizer G, Kantarjian H, Saunders GF: WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999, 13, 891–900.
  27. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D: High levels of Wilms’ tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long−term outcome. Blood 1997, 90, 1217–1225.
  28. Garg M, Moore H, Tobal K, Liu Yin JA: Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003, 123, 49–59.
  29. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P, Collado R, Sayas MJ, Sanz MA: Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004, 89, 926–933.
  30. Huang Z, Xiao B, Chen S, Li S, Liu Y, Liu J: Studies of WT1 gene expression in leukemia patients. Zhonghua Xue Ye Xue Za Zhi 2002, 23, 367–369.
  31. Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K, Sillaber C, Laczika K, Mitterbauer M, Zochbauer S, Mannhalter C, Haas OA, Lechner K, Jager U, Gaiger A: Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997, 11, 639–643.
  32. Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L: The coexpression of the apoptosis−related genes bcl−2 and WT1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002, 16, 846–854.
  33. Cilloni D, Saglio G: Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin Hematol 2003, 40, 37–41.
  34. Na IK, Kreuzer KA, Lupberger J, Dorken B, Coutre P: Quantitative RT−PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res 2005, 29, 343–345.
  35. Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege−Cambrin G, Alberti D, Baccarani M, Saglio G: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004, 101, 979–988.
  36. Uzunel M, Ringden O: Poor correlation of kinetics between BCR−ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 33, 47–52.
  37. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G: Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003, 21, 1988–1995.
  38. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H: The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999, 13, 393–399.
  39. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H: Wilms tumor gene peptide−based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003, 78, 56–61.
  40. Baird PN, Simmons PJ: Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997, 25, 312–320.
  41. Maurer U, Brieger J, Weidmann E: Rhe Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997, 25, 945–950.
  42. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89, 1405–1412.
  43. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, Masuda T, Kim EH, Tsuboi A, Oka Y, Soma T, Ogawa H, Sugiyama H: Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002, 116, 409–420.
  44. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T, Sugiyama H: Wilms’ tumor gene (WT1) competes with differentiation−inducing signal in hematopoietic progenitor cells. Blood 1998, 91, 2969–2976.
  45. Mi Y, Wang L, Bian S, Meng Q, Chen G, Wang J: Effect of WT1 gene expression on cell growth and proliferation in myeloid leukemia cell lines. Chin Med J 1999, 112, 705–708.
  46. Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, Tisljar K, Priglinger S, Laczika K, Mitterbauer M, Novak M, Mitterbauer G, Mannhalter C, Haas OA, Lechner K, Jager U: Detection of the WT1 transcript by RT−PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998, 12, 1886–1894.
  47. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H: Long−term follow−up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996, 88, 2267–2278.
  48. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84, 3071–3079.
  49. Cilloni D, Saglio G: WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004, 112, 79–84.
  50. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P: WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single−centre study. Br J Haematol 2004, 125, 590–600.
  51. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege−Cambrin G, Guerrasio A, Divona M, Lo Coco F, Saglio G: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002,16, 2115–2121.
  52. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101, 1698–1704.
  53. Ogawa H, Ikegame K, Kawakami M, Tamaki H: WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma 2004, 45, 1747–1753.
  54. Sugiyama H: Wilms’ tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 1998, 30, 55–61.
  55. Gaiger A, Reese V, Disis ML, Cheever MA: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000, 96, 1480–1489.
  56. Tsuboi A, Oka Y, Ogawa H, Eliseeva OA, li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H: Cytotoxic T−lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000, 20, 195–202.
  57. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ: Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95, 2198–2203.
  58. Ohminami H, Yasukawa M, Fujita S: HLA class I−restricted lysis of leukemia cells by a CD8(+) cytotoxic T−lymphocyte clone specific for WT1 peptide. Blood 2000, 95, 286–293.
  59. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H: Human cytotoxic T−lymphocyte responses specific for peptides of the wild−type Wilms’ tumor gene (WT1) product. Immunogenetics 2000, 51, 99–107.
  60. Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, Ogg G, McMichael A, Epenetos A, Goulmy E, Stauss HJ: Use of B cell−bound HLA−A2 class I monomers to generate high−avidity, allo−restricted CTLs against the leukemia−associated protein Wilms tumor antigen. Blood 2004, 103, 4613–4615.
  61. Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T: Generation of human tumor−specific, HLA class I−restricted Th1 and Tc1 cells by cell engineering with tumor peptide−specific T cell receptor genes. Blood 2005, 106, 470–476.
  62. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, Yasukawa M: Direct recognition and lysis of leukemia cells by WT1−specific CD4+ T lymphocytes in an HLA class II−restricted manner. Blood 2005, 106, 1415–1418.
  63. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99, 3272–3279.
  64. Gaiger A, Carter L, Greinix H, Carter D, Mc Neill PD, Houghton RL, Cornellison CD, Vedvick TS, Skeiky YA, Cheever MA: WT1 specific serum antibodies in patients with leukemia. Clin Cancer Res 2001, 7, 761–765.
  65. Wu F, Oka Y, Tsuboi A, Elisseeva OA, Ogata K, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H: Th1−biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 2005, 19, 268–274.
  66. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H: Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol 2000, 164, 1873–1880.
  67. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004, 18, 165–166.
  68. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H: Induction of WT1 (Wilms’ tumor gene)−specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci 2004, 101, 1385–1390.
© Wroclaw Medical University